June 10, 2024 11:42 PM
FDA panel reviews Eli Lilly Alzheimer’s drug ahead of agency decision
Outside advisers to the U.S. Food and Drug Administration are meeting on Monday to assess whether Eli Lilly's LLY.N experimental Alzheimer's drug donanemab is safe and effective, ahead of the agency's decision on approving the drug. The FDA had been...